The development of cancer immunotherapy for Immune checkpoint inhibitors (ICI) resistant cancers has been a challenge. Current ICI-based combination therapy strategies have achieved some, albeit limited, success. A deeper understanding of Tumor Immunity in the Micro Environment (TIME) biology in the IO (Immuno-oncology) will unveil next-generation therapeutic strategies. The dynamic functional interplay within TME brings important insights into the design of effective combinatorial strategies against cancer.
With the advent of novel genomics, computational tools, and understanding of the complex pathways, it has become obvious that the future of cancer therapy relies on effective combinational immuno-therapies. However, the key to therapy success will be dependent to find the right combination and sequence across different lines of therapy.
Join our webinar to learn:
1. Emerging concepts and strategies for IO development focusing on the corrections of the immunological defects in the TME (Hot vs. Cold Tumors)
2. Progress in the synergistic design of immune-targeting combination therapies and challenges involved
3. Analyzing old and new waves of IO combinational therapy with perspectives on the latest momentum shifts
4. Challenges and new perspectives with a focus on patients who have progressed on Immunotherapy
Know more about FutureBridge Life Sciences Practice here.
Share your focus area or question to engage with our Analysts through the Business Objectives service.Submit My Business Objective
Our long-standing clients include some of the worlds leading brands and forward-thinking corporations.